

Bio Surveillance Bacteria in Nanoparticle

Vamshi P*

Department of Medical Sciences, University of Torino, Torino, Italy

Abstract

The application of nanotechnology to oncology is transforming cancer treatment and diagnosis while also

Keywords: Nanooncology; Nanotechnology

Introduction

Cleaning up metal waste and contamination may be done via microbial metal reduction. When metal ions are reduced by bacteria,

the production of NPs, a large variety of bacterial species have been employed in green nanotechnology [9]. For the purpose of creating NPs, researchers have begun to employ the biomass or cell extracts of bacteria. Bacteria are viewed as a possible biofactory for the synthesis of NPs such as gold, silver, platinum, palladium, titanium, titanium dioxide, magnetite, cadmium sulphide, and others. Magnetotactic bacteria and S layer bacteria are two well-known types of bacteria that may synthesise inorganic compounds. The bioreduction of ions or the creation of water insoluble complexes is a defence mechanism established by the bacteria to overcome such toxicity as the majority of metal ions are harmful to them [10].

Molecular Diagnostics for Personalized Oncology

Due to their ability to trigger malignant transformation, mutations in the TK genomic domains of a variety of growth factor receptors were given the moniker "driver" mutations. Targeted therapy may not be successful in all patients, despite early finding, particularly in cancers harbouring driver mutations. A minority of tumour cell subclones may exhibit genetic heterogeneity, the emergence of drug resistance

such as efflux pumps, metal efflux systems, inactivation and complexation of metals, impermeability to metals, a lack of specific metal transport systems, alteration of solubility and toxicity by changes in the redox state of the metal ions, extracellular precipitation of metals, and volatilization of toxic metals by enzymatic reactions.

The ability to create silver nanoparticles has been demonstrated, for instance, in *Pseudomonas stutzeri* AG 259 isolated from silver mines.

The biotechnological domains of biomineralization, bioremediation, bioleaching, and microbially induced corrosion processes are just a few examples of how microbes and metals interact and are crucial to these applications. Understanding of MIC processes as localised changes in surface chemistry caused by microbes. *In situ* and *in situ* cleanup of metal wastes and contaminations may both benefit from microbial metal reduction. Researchers have studied the mechanisms of nanoparticle synthesis and bioreduction and have concentrated their attention on reducing agents in bacteria and biochemical pathways leading to metal ion reduction in order to determine the relevance of metal reduction, biorecovery of heavy metals, and bioremediation of toxic ones. The importance of these agents prompted more research into the function and use of naturally occurring and genetically modified bacterial strains and other microorganisms in the bioremediation of radionuclide- and toxic metal-contaminated terrestrial environments.

These microorganisms were capable of mobilising and immobilising metals, and in some cases, the bacteria that could reduce metal ion.

Potential Futures

The time-consuming purifying processes and lack of knowledge of the mechanisms involved in the production of NPs utilising bacteria are major limitations. Controlling the particle size and shape as well as achieving monodispersity in the solution phase are significant difficulties that typically arise during the biosynthesis of NPs. Before this green bio-based technology will be a viable and competitive alternative for the industrial synthesis of NPs, it appears that a number of significant technological difficulties must be addressed. Scaling up for processing at the production level is a significant obstacle. Furthermore, little is known about the mechanistic aspects, and knowledge in this area is required for the economical and logical growth of nanoparticle biosynthesis.

Discussion

A tremendous amount of work has been put into designing and creating nanometer-sized targeted probes for cancer diagnosis and therapy over the past 20 years. These probes combine a variety of features and diverse functions, including stability in the circulation, accumulation to particular areas, responsiveness to local cues, effective intracellular drug delivery, and multimodality of action. The morphological characteristics of the tumour are provided by magnetic iron oxide (ION) nanoparticles employed as an MRI contrast agent in cancer imaging, and the therapy response is continuously tracked. Highly lymphotropic superparamagnetic iron oxide nanoparticles (SPIONs), which simultaneously combine high-resolution MRI with optical imaging, have been utilised successfully for micrometastasis screening in patients with prostate cancer who have undergone surgical lymph node resection or biopsy. Studies are being conducted to address these issues and determine the optimum methods for the extraction and purification of the metal NPs produced by bacteria (either through intercellular or extracellular synthesis) for subsequent applications. Additional processing steps are needed, such as ultrasonic treatment or a reaction with the appropriate detergents, to release the NPs created intracellularly. The recovery of valuable metals from mine wastes and metal leachates can take advantage of this. Metal NPs embedded

in biomatrix could be employed as catalysts in a variety of chemical processes. This will aid in keeping the NPs in place for ongoing use in bioreactors. The generated NPs can be removed from the cells using physicochemical techniques as freeze-thawing, heating procedures, and osmotic shock.

Conclusion

Cancer diagnosis is frequently made in the latter stages, when conventional cancer therapy is limited by side effects and disadvantages. Fresh molecular biomarkers give rise to new optimism; for instance, miRNAs enable very early, accurate, and cutting-edge cancer diagnosis and therapy and enhance prognosis. Personalized anticancer therapies began with particular antitumor mAbs and TKIs, but mAbs are typically useless as second-line therapy and TKIs quickly cause resistance. A molecular anticancer strategy that is specifically targeted at a single cancer cell is needed for personalised oncology to be effective. The molecular signature of the tumour that needs to be treated must therefore be thoroughly diagnosed. Orthotopic tumour models using patient-derived xenografts in immunodeficient mice enable drug response prediction and personalised anticancer treatment. The evaluation of second-generation polymeric nanoparticles has already been approved. The binding to several cell ligands is made easier by the modification of NPs, which also improves their physicochemical properties for drug targeting, release, and clearance. Cancer theranostics is a newly emerging field. There are many different cancer types that could benefit from the use of recently produced nanoparticles, including malignancies that exhibit a stem-cell characteristic. These nanoparticles were functionalized to give multifunctional nanoplatforms in melanoma. Theranostics, which is molecularly focused, can monitor very successful targeted therapy while simultaneously enabling tumour detection at the level of a single cell and combining it with tumour diagnostic imaging. Real-time detection of nanovectors localised at the target areas and immediate visual evaluation of therapeutic effect on tumour cells are made possible by a dual diagnostic and therapeutic method combined with selective targeting.

The stability and aggregation of the biosynthesized NPs, control of crystal growth, form, size, and size distribution are the most significant challenges now encountered with bio-based techniques, which are still in the development stages. Additionally, biologically produced NPs are more polydisperse than those made chemically. The control of NP characteristics can be achieved by optimising crucial factors that affect cellular activities, enzymatic reactions, and organisms' growth conditions.

Mechanistic issues have not been thoroughly and precisely articulated or explored. Therefore, more thorough research is required to understand the precise mechanisms of reaction and pinpoint the proteins and enzymes involved in nanoparticle manufacturing. The employment of bacteria in the large-scale synthesis of NPs is intriguing because it eliminates the need for risky, pricey, and poisonous chemical ingredients in the synthesis and stabilisation procedures. These natural nanofactories appear to be capable of producing stable NPs with well-defined sizes, morphologies, and compositions by tuning the reaction conditions and choosing the right bacteria.

Acknowledgement

The author would like to acknowledge his Department of Medical Sciences, University of Torino, Torino, Italy for their support during this work.

Conflicts of Interest

The author has no known conflicts of interest associated with this paper.

References

F&A Oj-^~kCEU&U&^ { AUU&O} :æ!^kCEU&U , áæ!T O&O|æ&æ , ^!PCE!GEG&AT ~|c&~ } &c! [}æ|& ^! ~| [•^! }æ } [&! ^•cæ|!D { ^cæ|! [ç&â^!@^ à!i&â&] @ [c [É&^*!æ&æc! []É!æ } ç&à&c^!iæ|!æ } á!